

One Small Cap Story: Vericel

Transcript of a video recorded on August 23, 2019

Behan: Small caps have an incredible number of securities and very many of these have really exciting growth prospects in front of them. Can you talk to us about perhaps a security that gives an example of the space that you invest in?

Nelson: There's a company in our portfolio called Vericel, which is a healthcare company that makes cartilage repair tissue. They'll take a biopsy of the cartilage from a patient's knee—they've got an FDA product for the knee specifically—and they'll take that biopsy and they'll grow that cartilage further and then reinsert it back into the knee surgically. It's a repair-and-recovery type situation, and that procedure is much more beneficial to the patient, as there's less pain involved and there's more function to the knee.

That sounds great as a patient. The reason we like it as a small cap investment is that we look for sustainability of growth and we look for underestimated growth. Those two things are really important to any investment we make. Vericel is in somewhat of an early-stage situation where they've only called on about 900 of the 3,000 sports medicine doctors that are out there. So, they've got a lot of runway to further penetrate the sports medicine surgeon's world, and they're starting to tap into the orthopedic surgeon world, which is another 1,500 to 2,000 surgeons.

There's a lot of runway for them to have these surgeons get trained on their product (the product's called MACI and M-A-C-I is the acronym), so there's likely to be a sustained growth profile for that reason. They're also improving the conversion rate from the time a patient takes that original biopsy to the conversion to actually getting a surgery to have that cartilage reinserted back into the patient. That metric is improving and it's also resulting in increased growth for the company.

So, that's the sustainable growth portion of the thought process, and then there's the underestimated growth portion of how we think and how we look at an investment.

Vericel scores really well there. They have a track record of meeting and exceeding analyst expectations, and as I look forward into what the expectations are for MACI for the next several quarters, they're projecting a pretty sizable deceleration in the growth rate. We're not sure it's actually going to play out that way. We think they're most likely going to be able to sustain that growth at the current levels that we're seeing.



ROBERT F. BEHAN, CFA
President and Head of
Global Distribution



BRANDON M. NELSON, CFA
Senior Portfolio Manager
Calamos Timpani Small Cap
Growth Fund (CTSIX)

We're excited about it. It checks our boxes. It's a little below the radar screen. It's about \$750 million in market cap, but I think it's a good example of the kind of stock we look for.

Behan: Sounds like a perfect company for you. Can you tell us about the process for adding a security or company like that to your portfolio?

Nelson: So, we first found this one at a conference. So, myself and the rest of our team attend research conferences regularly. And this was a sort of routine conference we were attending—a growth conference. We liked what we heard at the initial conference presentation and further pursued it. We talked to management, had them in our office a few weeks later, and that led to a much higher level of conviction and a deeper understanding of the investment. That's when we took the position.

It was "in-the-trenches" research, we'll call it, where we're meeting with companies and understanding their businesses and trying to get our arms around the investment. And that's very typical of what we'll do, not just with Vericel, but with any stock we're looking at.

Video recorded 8/23/19.

Opinions and estimates offered constitute our judgment and are subject to change without notice, as are statements of financial market trends, which are based on current market conditions. We believe the information provided here is reliable, but do not warrant its accuracy or completeness. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The views and strategies described may not be suitable for all investors. This material has been prepared for informational purposes only, and is not intended to provide, and should not be relied on for, accounting, legal or tax advice. References to future returns are not promises or even estimates of actual returns a client portfolio may achieve. Any forecasts contained herein are for illustrative purposes only and are not to be relied upon as advice or interpreted as a recommendation.

Important Risk Information. An investment in the Fund(s) is subject to risks, and you could lose money on your investment in the Fund(s). There can be no assurance that the Fund(s) will achieve its investment objective. Your investment in the Fund(s) is not a deposit in a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation (FDIC) or any other government agency. The risks associated with an investment in the Fund(s) can increase during times of significant market volatility. The Fund(s) also has specific principal risks, which are described below. More detailed information regarding these risks can be found in the Fund's prospectus.

It should not be assumed that any of the securities transactions or holdings discussed were or will prove to be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance of the securities discussed herein.

The principal risks of investing in the Calamos Timpani Small Cap Growth Fund include: equity securities risk consisting of market prices declining in general, growth stock risk consisting of potential increased volatility due to securities trading at higher multiples, and portfolio selection risk.

The Fund invests in small capitalization companies, which are often more volatile and less liquid than investments in larger companies. As a result of political or economic instability in foreign countries, there can be special risks associated with investing in foreign securities, including fluctuations in currency exchange rates, increased price volatility and difficulty obtaining information. In addition, emerging markets may present additional risk due to potential for greater economic and political instability in less developed countries.

Active management does not guarantee investment returns or eliminate the risk of loss. It should not be assumed that any securities mentioned in this recording will be profitable or experience equal performance in the future.

CALAMOS[®]
INVESTMENTS

Calamos Financial Services LLC, Distributor
2020 Calamos Court | Naperville, IL 60563-2787
800.582.6959 | www.calamos.com | caminfo@calamos.com
© 2019 Calamos Investments LLC. All Rights Reserved.
Calamos[®] and Calamos Investments[®] are registered trademarks
of Calamos Investments LLC.
801721 0919